China Clinical Trials

China has emerged as a significant player in the global clinical trials landscape, with a growing number of trials being conducted within the country.

The need to perform studies for your device or IVD for the purposes of product approval in China varies depending on their risk classification, whether exemptions exist, and the legal requirements for clinical data.

The complexities and regulatory requirements surrounding clinical trial approvals in China can affect the efficiency of the trials, with necessary documentation and quality control challenges.

Urgent clinical development
Clinical evidence

Considerations Before Starting CTs in China

Clinical Trial Exemptions

Qualifying for an exemption usually means that the device or the IVD is listed in their respective exemption catalogues:

NMPA Medical Device Clinical Evaluation Exemption Catalogue
NMPA IVD Clinical Evaluation Exemption Catalogue.

Although IVDs included in the exemption list can avoid general trials, clinical studies in China are usually unavoidable.
The National Medical Products Administration (NMPA) publishes and updates these clinical evaluation exemption lists, known as catalogues, on a regular basis. Please check with us to determine if your product is on these lists.

Predicate Comparison

A clinical study may not be necessary if you can demonstrate substantial equivalence to an approved device or IVD in the People's Republic of China (PRC) through a CER.

Please note that if there are significant differences in the intended use, technical features, or biological characteristics compared to devices already approved in the PRC, the product is generally classified as a new type of device. In such cases, the predicate device pathway is typically not applicable, and a clinical evaluation is usually required based on study data—either from a trial conducted overseas or in the PRC.

Use of Overseas Data

If the declared product has undergone studies outside the PRC that meet or exceed the requirements of Chinese regulations, the product can avoid having to undertake studies in the PRC.

Use of Real-World Data

Another alternative is the use of Real-World Data from sources such as patient-generated data or data derived from electronic health records. As specific guidelines for RWD have not yet been released, this data is typically used as supplementary information in Clinical Evaluation Reports.

Risk Classification

Clinical trials are not necessary for Class I devices or IVDs.
Class II & III devices and IVDs may qualify for an exemption.

China Clinical Trials Registry

The Chinese clinical trial registry, established by the NMPA, serves as the primary registry, providing a centralized platform for trial application, approval, and monitoring.

This registry is a crucial tool for ensuring transparency and accountability in clinical research. It allows for systematic tracking, from their inception to completion, ensuring they meet the stringent regulatory standards set by the NMPA. This registry not only facilitates the approval process but also helps in maintaining high standards of quality control and compliance with the Personal Information Protection Law.

Role of a China Agent

Clinical Trial Process for MDs & IVDs in China

There is a structured process and procedures to follow to ensure the study meets NMPA regulatory requirements. Here is an overview of the key steps:

1

Development & Strategy Consulting

Relevant clinical endpoints to assess safety and effectiveness
Study design and methodology
Patient selection criteria
Data collection and analysis methods

2

Ethics Approval & Trial Registration

Submitting the protocol for ethics committee approval at the study site(s).
For those involving Class II devices and certain Class III products that meet specified conditions, the applicant must submit a notification to the drug regulatory authority of the corresponding province and obtain a filing number before commencing the study in humans.
For those involving high-risk Class III devices (such as implants or life-support devices), the applicant must submit an application to the NMPA. The study may proceed only after the application has passed a technical review and received authorization. The NMPA must issue a decision within 60 working days of accepting the application; if no decision is issued within this timeframe, the application is considered approved by default.

3

Conducting the Clinical Trial

Patient recruitment
Device application and monitoring
Data collection and interim analysis.

For implants or other high-risk devices, preclinical animal studies are often required before the human trial stage to validate safety and biocompatibility.

4

Data Collection, Analysis, & Clinical Trial Report

The collected data is analyzed and summarized.
Patient A final Clinical Trial Report (CTR) is prepared, detailing the outcomes.

5

Submission to the NMPA

The CTR and trial protocol must be included in the submission dossier when applying for device and IVD marketing authorization. The NMPA will review the data to assess whether the necessary safety and efficacy standards have been met.

Our China Clinical Trials Services

We make medical device and in vitro diagnostic (IVD) CTs in the PRC easier by guiding you through Chinese regulations, Good Clinical Practice (GCP) standards, and ethical requirements. With our expert support, we help you navigate the process smoothly, stay compliant, and move efficiently toward marketing authorization.

Our services include:

CT Strategy & Regulatory Assessment

We design tailored clinical development strategies aligned with product type, classification, and regional requirements. Our roadmaps integrate regulatory timelines, resource planning, and clinical milestones to support both early-stage feasibility and late-stage execution.

Feasibility analysis: Assess whether requirements or exemptions apply.
Regulatory roadmap: Develop a customized strategy for NMPA approval.
Compliance evaluation: Ensure adherence to the PRC's Good Clinical Practice (GCP) for Medical Devices (Decree #25).

Type Testing & Pre-Trial Preparation

Local type testing coordination at an NMPA-designated lab to meet China’s standards.
Clinical trial protocol (CTP) drafting, ensuring alignment with NMPA requirements.
Ethics Committee (EC) approval support, including preparation of required documentation.
Registration of the CT with NMPA where applicable.

Clinical Trial Execution Support

Selection of accredited clinical trial sites in China.
Negotiation of contracts with sites and medical institutions.
Monitoring of trial progress, ensuring compliance with protocol and GCP guidelines.
Adverse event reporting and safety monitoring.

Data Management & Submission

Data collection and analysis in compliance with NMPA submission standards.
Preparation of the Clinical Trial Report (CTR), summarizing results for regulatory review.
Submission to NMPA as part of the registration dossier for device or IVD market authorization.

Useful Articles

View More

Malaysia Drug–Medical Device Combination Products: A Guide to Classification & Regulatory Pathways

Learn how Malaysia classifies drug–medical device combination products and how the PMOA determines pathways and compliance responsibilities.

April 16, 2026
Malaysia Drug–Medical Device Combination Products: A Guide to Classification & Regulatory Pathways
Laboratory professional in protective eyewear, hair cover, sterile gown, and blue nitrile gloves examining a filled syringe in a clean laboratory environment.

Entering China’s Intraocular Lens (IOL) Market: NMPA Registration Requirements for Foreign Manufacturers

Understand the pathway for intraocular lens (IOL) registration in China, including NMPA requirements and key compliance steps.

April 15, 2026
Entering China’s Intraocular Lens (IOL) Market: NMPA Registration Requirements for Foreign Manufacturers
A close-up of an eye with a transparent intraocular lens held by surgical tweezers positioned in front of the pupil, illustrating ophthalmic medical device use. The visual supports themes of regulatory compliance, product registration, and market access

China Hyaluronic Acid Registration: A Complete Guide

A complete guide to China hyaluronic acid registration, covering classification, NMPA requirements, and compliance steps for manufacturers.

April 16, 2026
China Hyaluronic Acid Registration: A Complete Guide
China Hyaluronic Acid Registration: A Complete Guide

Indonesia's Halal Requirements for Medical Devices: What Manufacturers and Importers Need to Know

Learn which products are covered by Indonesia's halal framework, the labeling and manufacturing obligations, and phased compliance timelines.

April 15, 2026
Indonesia's Halal Requirements for Medical Devices: What Manufacturers and Importers Need to Know
Indonesia's Halal Requirements for Medical Devices: What Manufacturers and Importers Need to Know

Medical Device Registration in Indonesia: A Practical Guide for Foreign Manufacturers

Learn how to register medical devices in Indonesia, including Authorized Representative rules, classification, dossiers, timelines, and fees.

April 15, 2026
Medical Device Registration in Indonesia: A Practical Guide for Foreign Manufacturers
Medical Device Registration in Indonesia: A Practical Guide for Foreign Manufacturers

Medical Devices in China: A Regulatory Glossary for NMPA Compliance

Practical China medical device glossary explaining NMPA terms, with clear comparisons to US FDA and EU MDR terminology.

April 15, 2026
Medical Devices in China: A Regulatory Glossary for NMPA Compliance
Medical Devices in China: A Regulatory Glossary for NMPA Compliance
Previous
Previous

Explore Related Services

Whether you’re just starting out or are a blue-chip, access our wide range of services and solutions to help your business thrive.

Medical Device Registration

We guide you through every step of the process. We take care of compliance with NMPA requirements, advising you on the optimal market entry pathway, and helping you through the whole process.

Drug Device Combination Products

We assist with the classification, registration and compliance of combination products in the PRC, whether drug or device led.

China NMPA IVD Registration

We support you through every stage of the process, ensuring compliance with NMPA regulations. From choosing the best market entry strategy to handling regulatory requirements, we make the process as smooth as possible.

NMPA Clinical Evaluation Report

Clinical Evaluation Reports can avoid the need for a China clinical trial in some instances. Our experts can advise and prepare NMPA compliant CERs.

NMPA Legal Agent

We are your authorized representative in China, and fulfill your registrations and filings as well as ensuring compliance and PMS requirements.

NMPA Type Testing

Our on-site test engineers coordinate and supervise type tests of your medical products in NMPA-accredited laboratories.

Device PMS & Vigilance

The NMPA is placing greater focus on Post-Market Surveillance (PMS) such as more in-market sampling inspections and regular standard changes.Our specialist PMS team means you stay up to date with the many aspects of compliance.

Regulatory Outsourcing

If you are seeking specific specialist expertise or have ongoing resource-intensive needs, we have a variety of solutions to meet your needs.

China Device Quality Compliance

We help you achieve and ensure ongoing compliance with Chinese requirements.Our experts prepare and assist you for official NMPA inspections.

How We’ve Helped Clients with Our Expert Guidance

Read about how we work with clients to find solutions, bringing together deep industry knowledge with leading talent.

View More
April 18, 2026

China Manufacture License Renewal for Level A2 Pressure Vessels

How Cisema Supported Inox Torres Group, S.L. in Successfully Renewing its China Manufacture License (SELO) for Level A2 Pressure Vessels

The China Manufacture License (CML), also known as the SELO license, is a mandatory requirement for manufacturers of pressure equipment intended for the Chinese market. Inox Torres Group, S.L.’s manufacturing site produces high-pressure vessels falling under the Level A2 scope. This license ensures compliance with China’s stringent quality and safety regulations for special equipment.

The Challenge: Managing SELO Complexity for High-Risk Equipment

Renewing a SELO license for Level A2 pressure vessels required careful coordination across regulatory, technical, and cultural dimensions.

  • Navigating Regulatory Complexity
    Navigating the complex and evolving SELO regulatory framework, particularly for high-risk products under Level A2, required meticulous planning and real-time compliance updates.
  • Ensuring Audit Readiness
    Inox Torres Group, S.L. needed to ensure all documentation and procedures were fully up to date and to select an appropriate demo product that met inspection requirements.
  • Managing Inspector Expectations
    Success depended on understanding the unspoken cultural and procedural expectations of SELO inspectors, including hosting and on-site hospitality.

Our Solution: Full-Spectrum SELO Audit Support

Recognizing the high stakes of SELO license renewal, Inox Torres Group, S.L. engaged Cisema for comprehensive regulatory and strategic support.

  • Reviewed the Quality Management System
    Cisema led the review and upgrade of the customer’s quality management system in line with the latest Chinese requirements, including a comprehensive gap analysis and revision of key documentation.
  • Audit Simulation & Preparation
    A preparatory remote audit simulation was conducted, walking through every step of the audit to ensure full readiness ahead of the on-site inspection.
  • Delivered On-Site Bilingual & Regulatory Support
    During the on-site audit, Cisema provided continuous bilingual support, interpreting inspector questions in real time and translating regulatory nuances for the customer.
  • Provided Culturally Appropriate Inspector Hosting
    Cisema arranged culturally appropriate corporate hospitality, helping establish a respectful and positive tone for the inspection. The team remained onsite throughout all audit days, including the weekend, to ensure no detail was overlooked.

The Outcome: Successful Renewal Without Disruption

Through hands-on execution and close coordination, the SELO renewal process was completed smoothly and efficiently.

  • Secured CML Renewal with Full A2 Status
    Inox Torres Group, S.L. successfully renewed its China Manufacture License for pressure vessels, maintaining its Level A2 classification.
  • Executed the Project Efficiently
    Full regulatory preparation and audit execution were completed within six months.
  • Achieved Seamless Inspector Coordination
    SELO inspectors were hosted and coordinated smoothly, with culturally aligned engagement throughout the audit.
  • Secured Regulatory Continuity  
    The renewal avoided operational disruptions and ensured compliance with updated SELO requirements.

Expertise and Efficiency: Acting as an Extension of the Client Team

Cisema’s experienced consultants acted as an extension of Inox Torres Group, S.L.’s regulatory and quality teams, providing both regulatory expertise and strategic foresight. Inspector concerns were anticipated and addressed proactively, transforming a potentially stressful process into a streamlined, well-orchestrated engagement with Chinese authorities.

Hands-on mentoring throughout the project helped the customer gain confidence and clarity in managing future SELO audits.

Why Choose Cisema

  • Strategic Regulatory Expertise: Deep understanding of Chinese bureaucracy, evolving SELO requirements, and inspector expectations.
  • Mentorship & Training: Step-by-step guidance that supported the customer’s quality team throughout the process.
  • Corporate Hospitality Excellence: Culturally aligned hosting that supports successful audit outcomes in China.
  • Audit Readiness & Precision: Gap analysis, audit simulation, and documentation refinement to pass SELO reviews efficiently.
  • End-To-End Support: Full management of the audit process, from document revision to on-site interpretation.

Further Information

Explore Cisema’s China Special Equipment (SELO) Certification services.

Learn More
China Manufacture License Renewal for Level A2 Pressure Vessels
Previous
Previous

Latest Insights

View More

Malaysia Introduces New e-IFU & Digital Labelling Guidance for Medical Devices

Malaysia’s MDA publishes the 7th edition of guidance on medical device labelling, with new e-labelling, e-IFU, and accessibility requirements

April 17, 2026
Malaysia Introduces New e-IFU & Digital Labelling Guidance for Medical Devices
Two professionals in an office review documentation for a HealthScreen glucose monitor while examining a computer display showing a product label with model number, barcode, and QR code. One person points to the code on the screen as the other reads.

Vietnam Cuts Advertising Red Tape for Healthcare Products

Vietnam’s MoH recently published Circular drops several healthcare advertising regulations and streamlines requirements for many categories.

April 17, 2026
Vietnam Cuts Advertising Red Tape for Healthcare Products

China NMPA Issues 26 Medical Device Standards Affecting Orthopedics, IVDs, & Software

The 26 new medical device standards cover orthopedic implants, IVDs, active devices, and software risk management.

April 17, 2026
China NMPA Issues 26 Medical Device Standards Affecting Orthopedics, IVDs, & Software

China Mandates Full UDI Compliance for All Medical Devices by 2029

China’s NMPA mandates full UDI coverage for all medical devices by 2029, linking compliance to registration, reimbursement, and market access.

April 17, 2026
China Mandates Full UDI Compliance for All Medical Devices by 2029

China NMPA Clarifies Pre-Review for Innovative Device Clinical Trials

China’s NMPA issues new guidance on clinical trial protocol pre-review for innovative devices, impacting overseas fast-track approvals.

April 17, 2026
China NMPA Clarifies Pre-Review for Innovative Device Clinical Trials

China NMPA Releases 2025 Medical Device Registration Data Report

China NMPA’s 2025 report highlights growth in medical device approvals, including advanced imported devices.

April 17, 2026
China NMPA Releases 2025 Medical Device Registration Data Report
Previous
Previous

Get in Touch with Our Life Sciences Team

And discover how we can support you in undertaking the Type Testing for your medical device or IVD in China.

Request Proposal